	C 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	659	825	970	1,094	1,135	1,195	1,244	1,561	1,806	2,155	2,489	2,716	2,529	2,387	2,565
Cost of Operating Revenue	555	668	777	880	912	943	974	1,279	1,437	1,588	2,018	2,252	2,048	1,914	1,686
Gross Profit	104	157	193	214	222	252	270	282	369	567	471	464	480	473	880
Gross Margin	15.8	19.0	19.9	19.6	19.6	21.1	21.7	18.1	20.5	26.3	18.9	17.1	19.0	19.8	34.3
Total Operating Expenses	604	729	850	956	997	1,041	1,082	1,393	1,589	1,764	2,206	2,457	2,259	2,153	2,323
Operating Profit	56	96	120	139	138	154	162	168	217	390	283	259	270	234	242
Operating Margin	8.5	11.7	12.4	12.7	12.2	12.9	13.0	10.8	12.0	18.1	11.4	9.5	10.7	9.8	9.4
Financing Income/(Expense) - Net	-25	-31	-36	-42	-47	-41	-38	-42	-36	-23	-22	-36	-35	-27	-34
Profit before Taxes	32	66	85	100	95	116	125	131	185	369	270	224	236	212	211
Income Taxes	10	21	24	22	27	34	42	41	44	89	65	58	64	44	16
Profit after Tax	22	45	62	77	69	82	82	90	141	280	205	166	171	168	195
PAT Margin	3.4	5.5	6.4	7.1	6.1	6.8	6.6	5.7	7.8	13.0	8.2	6.1	6.8	7.0	7.6
EPS - Basic - ex Extraordinary Items	2.32	4.72	6.28	7.98	7.09	8.57	8.73	9.51	15.17	30.09	22.14	17.96	18.65	18.35	21.36
EPS - Diluted - ex Extraordinary Items	2.32	4.72	6.28	7.98	7.09	8.57	8.73	9.51	15.17	30.09	22.14	17.96	18.65	18.35	21.36
EBIT	56	96	120	139	138	154	162	168	217	390	283	259	270	234	242
EBITDA	80	122	148	170	175	192	202	211	266	440	333	309	321	290	309
EBITDA Margin	12.1	14.8	15.3	15.5	15.4	16.1	16.2	13.5	14.7	20.4	13.4	11.4	12.7	12.2	12.1

Balance Sheet

Abridged

Understanding Balance Sheet

Aarti Drugs Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	IR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	327	408	457	526	565	571	737	784	899	1,057	1,393	1,492	1,321	1,338	1,468
Property Plant & Equipment - Net	277	296	378	463	520	589	626	655	655	684	767	862	1,035	1,133	1,284
Total Non-Current Assets	286	312	393	476	550	620	653	671	677	709	815	930	1,112	1,236	1,347
Total Assets	613	720	850	1,002	1,116	1,191	1,389	1,455	1,577	1,766	2,208	2,421	2,432	2,575	2,815
Total Current Liabilities	337	391	480	483	500	494	622	591	623	595	940	949	796	837	922
Long Term Debt	67	81	77	163	191	202	203	208	186	151	140	205	276	286	258
Total Non-Current Liabilities	99	121	119	211	269	297	312	321	301	257	232	279	355	368	344
Total Liabilities	436	512	599	694	769	791	934	912	924	853	1,172	1,229	1,150	1,205	1,266
Total Shareholders' Equity	176	208	251	308	347	400	455	543	652	913	1,036	1,192	1,282	1,369	1,549
Minority Interest	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0
Total Equity	176	208	251	308	347	400	455	543	652	913	1,036	1,193	1,282	1,369	1,549
Total Liabilities & Equity	613	720	850	1,002	1,116	1,191	1,389	1,455	1,577	1,766	2,208	2,421	2,432	2,575	2,815

Cash Flow

Abridged

Understanding Cash Flow Statement

Aarti Drugs Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	C 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	50.70	78.33	87.37	115.66	111.52	130.40	140.99	137.51	198.84	323.55	239.50	214.17	227.33	219.77	286.63
Working Capital - Increase/(Decrease)	-30.73	-33.89	-24.09	-49.58	-21.25	8.47	-105.19	-32.98	19.49	-185.99	-187.35	-116.34	102.78	3.59	-64.22
Net CF from Operating Activities	19.97	44.44	63.28	66.08	90.27	138.87	35.80	104.54	218.33	137.56	52.15	97.84	330.11	223.36	222.41
Capital Expenditures - Net	47.27	60.00	106.47	106.98	99.66	107.11	74.53	63.07	37.14	77.35	151.95	164.67	226.15	177.11	173.04
Net CF from Investing Activities	-48.59	-58.21	-106.01	-107.43	-99.66	-107.52	-74.53	-63.07	-34.52	-77.35	-151.95	-164.67	-226.15	-176.84	-174.58
Dividends Paid - Cash - Total	5.45	10.90	13.92	22.67	23.61	-	2.43	2.43	7.03	23.21	9.51	9.40	9.27	9.06	18.17
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-27.00	-24.06	-	-25.39	-	-60.00	0.76	-59.85	-59.85	-
Debt - LT & ST - Issuance/(Retirement) - Total	33.75	22.60	58.17	63.06	34.24	-4.81	65.86	-37.20	-147.82	-34.97	195.95	61.37	-22.28	33.56	-26.98
Net Cash Flow from Financing Activities	28.30	11.70	44.25	40.39	10.63	-31.81	38.88	-40.11	-181.68	-58.17	112.60	52.73	-104.72	-48.68	-45.14
Free Cash Flow to Equity	6.45	7.05	14.98	22.16	24.86	26.95	27.13	4.26	33.36	25.25	96.14	-5.46	81.68	79.80	22.39
Free Operating CF net dividend	-32.75	-26.46	-57.17	-63.57	-33.00	30.08	-41.16	27.83	163.31	26.12	-109.33	-76.38	94.51	37.13	30.92
Free Operating CF	-27.30	-15.56	-43.24	-40.90	-9.39	30.08	-38.73	30.26	170.34	49.33	-99.82	-66.98	103.78	46.19	49.09

Business Segment Analysis

FY End:

Mar 25

Aarti Drugs Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmasuticals (100.0%)₹ 177.16 Cr

Revenue / Sales

Pharmasuticals (100.0%)₹ 2,387.03 Cr

Assets

Pharmasuticals (100.0%)₹ 2,574.68 Cr

Operating Income

Pharmasuticals (100.0%)₹ 234.45 Cr

Regional Segment Analysis

FY End:

Mar 25

Aarti Drugs Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (63.7%)₹ 1,521.70 CrOut of India (36.3%)₹ 865.33 Cr

Historical Segment Analysis

Track how Aarti Drugs Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmasuticals	48	88	152	165	226	177

Frequently Asked Questions

What is the revenue of Aarti Drugs Ltd.?

The latest trailing twelve month revenue of Aarti Drugs Ltd. is ₹ 2,565.31 Cr, reflecting a 1-year growth of 7.47% and a 3-year CAGR of -1.89%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Aarti Drugs Ltd.?

The latest trailing twelve month net profit (PAT) of Aarti Drugs Ltd. is ₹ 194.92 Cr, with a 3-year earnings CAGR of 5.95%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Aarti Drugs Ltd.?

The trailing twelve month EBITDA of Aarti Drugs Ltd. is approximately ₹ 242.22 Cr (based on an operating margin of 9.44%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Aarti Drugs Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Aarti Drugs Ltd. is 21.36. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Aarti Drugs Ltd.?

The debt-to-equity ratio of Aarti Drugs Ltd. stands at 0.37. The interest coverage ratio is 7.19x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Aarti Drugs Ltd.?

The estimated book value per share of Aarti Drugs Ltd. is 169.70 (derived from a P/B ratio of 2.49 and market price of ₹ 422.30), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Aarti Drugs Ltd.?

The trailing twelve month operating cash flow of Aarti Drugs Ltd. is ₹ 222.41 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Aarti Drugs Ltd. report consolidated or standalone financials?

Aarti Drugs Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.